Research & Development | Clinical Testing | Commercial Partnership
Precision Diagnostics Powered by Epigenetics
EpiSign™ is the global leader in epigenomic diagnostics and developer of the first-ever scientifically validated epigenomic diagnostic testing software for genetic conditions.
Pioneering Epigenetic Research & Development
EpiSign™ uses scientifically validated research to develop real-world healthcare tools that provide clearer answers and better outcomes.
Our Technology
EpiSign™ METRIC is the first-ever clinically validated epigenomic diagnostic testing software for genetic conditions. This proprietary platform gives partners exclusive access to the EpiSign™ Knowledge Database, the world’s most comprehensive epigenomic knowledge base in a practical application. METRIC provides innovative diagnostic insights from DNA methylation, delivering clear and actionable results for highly personalized healthcare.
METRIC uses machine learning-based algorithms to discover and identify DNA methylation patterns, or episignatures, associated with specific genetic conditions, including genetic and environmental exposure disorders. These episignatures are powered by the EpiSign™ Knowledge Database.
Healthcare providers can utilize EpiSign™ METRIC to determine if their patient has a detectable episignature. Leveraging microarray technology, a patient’s DNA methylation is compared to a growing list of genetic conditions with known episignature biomarkers. EpiSign™ METRIC is clinically validated through a network of diagnostic labs globally for screening individuals with suspected rare diseases and resolving ambiguous genetic findings often seen in these patients.
Episign Knowledge Database
127
Current menu provides episignatures for greater than 113 conditions.
140
Current EpiSign v5 classifier includes biomarkers for 126 genes/genetic regions.
Dozens of new conditions are being added annually.
Our Discovery Network
Ongoing collaboration with more than 100 institutions in over 20 countries in a global research effort to expand the clincal impact of EpiSign™ technology.
- Over 125 institutions
- Over 25 countries
- Active research in over 700 rare diseases
- Expand EpiSign™ mapping efforts to 1,000 syndromes in next 5 years
,
Our Reason
Everyone deserves insights that lead to better health outcomes. Our mission is to find and empower healthcare partners with cutting-edge research and technologies that enable accurate diagnoses, earlier interventions, and more effective treatments.
Pioneering Epigenetic Research
Explore our breakthroughs in epigenetics research. Our publications in top scientific journals highlight our role in advancing diagnostic approaches for genetic disorders. With a focus on real-world applications, we’re defining the future of genomic medicine.